# Co-trimoxazole

## Pharmacological Class

- **Class**: Antibacterial combination
- **Components**:

  1. `Trimethoprim` (dihydrofolate reductase inhibitor)
  2. `Sulfamethoxazole` (sulfonamide → inhibits dihydropteroate synthase)

- **Type**: Bactericidal (when combined)

## Mechanism of Action

- **Sequential blockade** of bacterial folate synthesis:

  - Sulfamethoxazole → inhibits dihydropteroate synthase
  - Trimethoprim → inhibits dihydrofolate reductase
    → ↓ Tetrahydrofolic acid → ↓ DNA, RNA, protein synthesis
    → Bacterial death

## Indications

1. **Bacterial Infections**:

   - UTIs (uncomplicated and complicated)
   - Respiratory tract infections (e.g., bronchitis, otitis media)
   - Gastrointestinal infections (e.g., _Shigella_, _Salmonella_, _E. coli_)
   - Nocardiosis
   - Typhoid fever

2. **Opportunistic Infections**:

   - **Pneumocystis jirovecii pneumonia (PCP)** – prophylaxis and treatment
   - **Toxoplasmosis** – in immunocompromised patients

## Contraindications

- Hypersensitivity to sulfonamides or trimethoprim
- Severe renal or hepatic impairment
- Megaloblastic anemia due to folate deficiency
- Infants \<6 weeks (risk of kernicterus)
- History of drug-induced thrombocytopenia with sulfonamides

## Side Effects

1. **Common**:

   - Nausea, vomiting, anorexia
   - Rash

2. **Serious**:

   - Stevens–Johnson syndrome / Toxic epidermal necrolysis
   - Bone marrow suppression (e.g., agranulocytosis, thrombocytopenia)
   - Hyperkalemia
   - Crystalluria, interstitial nephritis
   - Aseptic meningitis (rare)
   - Kernicterus (neonates)

## Route of Administration

- **Oral** (tablet, suspension)
- **IV infusion**

## Dosage

### Adult:

- **Standard dose**:

  - `800 mg sulfamethoxazole + 160 mg trimethoprim` (1 double strength tablet) twice daily

- **PCP treatment**:

  - `15–20 mg/kg/day (trimethoprim)` IV or PO in divided doses for 14–21 days

- **PCP prophylaxis**:

  - `800/160 mg once daily` or `400/80 mg twice daily`

### Children:

- **Oral**: `4 mg/kg trimethoprim + 20 mg/kg sulfamethoxazole` per dose twice daily
- **PCP**:

  - **Treatment**: `15–20 mg/kg/day (trimethoprim)` divided every 6–8 hours
  - **Prophylaxis**: `150 mg/m²/day (trimethoprim)` once daily or three times a week

## Use in Pregnancy

- **Trimester-specific risk**:

  - **1st trimester**: Avoid if possible (folate antagonist → neural tube defects)
  - **3rd trimester**: Risk of neonatal jaundice (kernicterus)

- Use only if **benefits outweigh risks**
- **Folic acid supplementation** recommended if used

## Use in Lactating Mothers

- Excreted in breast milk
- **Generally safe**, except in:

  - Premature infants
  - Infants \<6 weeks (kernicterus risk due to sulfonamide)
